Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.

Thumbnail
View/Open
Published version (2.444Mb)
Date
2017-05
ICR Author
Klampatsa, Astero
Author
Klampatsa, A
Achkova, DY
Davies, DM
Parente-Pereira, AC
Woodman, N
Rosekilly, J
Osborne, G
Thayaparan, T
Bille, A
Sheaf, M
Spicer, JF
King, J
Maher, J
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one ErbB family member was expressed in 88% of tumors. To exploit ErbB dysregulation in this disease, patient T-cells were engineered by retroviral transduction to express a panErbB-targeted chimeric antigen receptor (CAR), co-expressed with a chimeric cytokine receptor that allows interleukin (IL)-4 mediated CAR T-cell proliferation. This combination is referred to as T4 immunotherapy. T-cells from mesothelioma patients were uniformly amenable to T4 genetic modification and expansion/enrichment thereafter using IL-4. Patient-derived T4<sup>+</sup> T-cells were activated upon contact with a panel of four mesothelioma cell lines, leading to cytotoxicity and cytokine release in all cases. Adoptive transfer of T4 immunotherapy to SCID Beige mice with an established bioluminescent LO68 mesothelioma xenograft was followed by regression or eradication of disease in all animals. Despite the established ability of T4 immunotherapy to elicit cytokine release syndrome in SCID Beige mice, therapy was very well tolerated. These findings provide a strong rationale for the clinical evaluation of intracavitary T4 immunotherapy to treat mesothelioma.
URI
https://repository.icr.ac.uk/handle/internal/4108
DOI
https://doi.org/10.1016/j.canlet.2017.02.015
Collections
  • Cancer Therapeutics
Subject
T-Lymphocytes
Lymphocytes, Tumor-Infiltrating
Cell Line, Tumor
Animals
Humans
Mice, SCID
Mesothelioma
Lung Neoplasms
Pleural Neoplasms
Receptor, erbB-2
Receptors, Antigen, T-Cell
Recombinant Fusion Proteins
Interleukin-4
Immunotherapy, Adoptive
Tumor Burden
Coculture Techniques
Xenograft Model Antitumor Assays
Transduction, Genetic
Time Factors
Genetic Therapy
Receptor, ErbB-4
ErbB Receptors
Mesothelioma, Malignant
Research team
Thoracic Oncology Immunotherapy Group (TOIG)
Language
eng
Date accepted
2017-02-10
License start date
2017-05
Citation
Cancer letters, 2017, 393 pp. 52 - 59

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.